Eli Lilly has reported positive topline results from two additional Phase 3 studies in its TRIUMPH clinical development programme, further establishing the efficacy of retatrutide, an investigational first-in-class triple hormone receptor agonist targeting glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. The TRIUMPH-2 and TRIUMPH-3 trials evaluated retatrutide in adults with obesity complicated by type 2 diabetes and established cardiovascular disease, respectively. Both studies successfully met their primary efficacy endpoints after 80 weeks of treatment.
A large population-based screening study published in JAMA examined more than 220,000 children in Germany to detect early, presymptomatic type 1 diabetes using islet autoantibody testing. The study aimed to understand how common early-stage disease is and how it progresses over time in the general pediatric population.
GSK has reported promising clinical data for its investigational B7-H4-targeted antibody–drug conjugate (ADC), mocertatug rezetecan (also known as GSK5733584), in patients with gynaecological cancers, including ovarian and endometrial malignancies. These cancers often present at advanced stages and are associated with poor prognosis, particularly in patients who develop resistance to standard therapies such as platinum-based chemotherapy. The emergence of targeted therapies like ADCs represents a significant advancement in addressing these unmet clinical needs.
The emergence of oral glucagon-like peptide-1 (GLP-1) receptor agonists marks a significant advancement in obesity pharmacotherapy, offering needle-free alternatives to injectable agents. In this context, a new population-adjusted indirect treatment comparison (ITC), to be presented at the Obesity Medicine Association (OMA) 2026 annual meeting, evaluated the relative efficacy and tolerability of oral semaglutide 25 mg (Wegovy® pill) versus orforglipron 36 mg.
The role and optimal duration of beta-blocker therapy following myocardial infarction (MI) have been increasingly questioned in the contemporary era of advanced reperfusion strategies and secondary prevention therapies. In a recent study published in the New England Journal of Medicine, investigators evaluated the safety and clinical outcomes associated with discontinuation of long-term beta-blocker therapy in stable post-MI patients without clear ongoing indications such as heart failure or reduced left ventricular ejection fraction (LVEF).
